Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate ProgressGlobeNewsWire • 08/07/24
Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024GlobeNewsWire • 07/31/24
Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung CancerGlobeNewsWire • 07/11/24
Revolution Medicines (RVMD) Moves 11.0% Higher: Will This Strength Last?Zacks Investment Research • 07/10/24
Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024GlobeNewsWire • 07/08/24
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Revolution Medicines, Inc. (NASDAQ: RVMD)PRNewsWire • 07/08/24
Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare ConferenceGlobeNewsWire • 06/05/24
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate ProgressGlobeNewsWire • 05/08/24
Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024GlobeNewsWire • 05/01/24
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) ProteinsGlobeNewsWire • 04/09/24
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) ProteinsGlobeNewsWire • 04/08/24
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024GlobeNewsWire • 03/28/24
Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 02/26/24
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate ProgressGlobeNewsWire • 02/26/24
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024GlobeNewsWire • 02/20/24
Wall Street Analysts See a 27.5% Upside in Revolution Medicines, Inc. (RVMD): Can the Stock Really Move This High?Zacks Investment Research • 01/17/24
Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/04/24